Search

Mobic

Mobic

meloxicam

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH
Concise Prescribing Info
Contents
Meloxicam
Indications/Uses
Symptomatic treatment of painful OA (arthrosis, degenerative joint disease), RA, ankylosing spondylitis.
Click to view Mobic detailed prescribing information
Dosage/Direction for Use
OA 7.5 mg daily, may be increased to 15 mg daily. RA & ankylosing spondylitis 15 mg daily, may be reduced to 7.5 mg daily.
Click to view Mobic detailed prescribing information
Overdosage
View Mobic overdosage for action to be taken in the event of an overdose.
Administration
Should be taken with food.
Contraindications
Hypersensitivity to meloxicam, ASA or NSAIDs. Peri-op pain in CABG surgery setting. Active or recent GI ulceration/perforation; active inflammatory bowel disease (Crohn's disease or ulcerative colitis); overt GI bleeding, recent cerebrovascular bleeding or established systemic bleeding disorders; severe uncontrolled heart failure. Severe hepatic insufficiency. Non-dialysed severe renal insufficiency. Pregnancy & lactation.
Click to view Mobic detailed prescribing information
Warnings
For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Mobic detailed prescribing information
Special Precautions
Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. Patients w/ history of GI disease; other risk factors associated w/ PUD eg, alcoholism, smoking, corticosteroid therapy; CV disease or risk factors for CV disease; decreased renal blood flow or vol; dehydration, CHF; recent major surgical procedures leading to hypovolaemia. May mask symptoms of an underlying infectious disease. Not to be taken by patients w/ galactose intolerance eg, galactosaemia. Not to be co-administered w/ other NSAIDs. Concomitant use w/ anticoagulants, diuretic, ACE inhibitor or AIIA. May affect ability to drive & use machines. Hepatic cirrhosis, nephrotic syndrome, overt renal disease; end-stage renal failure on haemodialysis. May impair fertility. Not recommended in women of childbearing potential. Not to be used in childn & adolescents. Elderly, frail or debilitated patients.
Click to view Mobic detailed prescribing information
Adverse Reactions
Headache; abdominal pain, dyspepsia, diarrhoea, nausea, vomiting.
Drug Interactions
Increased risk of GI ulcers & bleeding w/ other prostaglandin synthetase inhibitors including glucocorticoids & salicylates. Increased risk of bleeding w/ oral anticoagulants, systemically-administered heparin, thrombolytics, anitiplatelet drugs, SSRIs. Increased lithium plasma levels. Increased plasma conc of MTX. Decreased IUD efficacy. Potential for acute renal insufficiency in dehydrated patients w/ diuretics. Reduced effect of antihypertensives eg, β-blockers, ACE inhibitors, vasodilators. Synergistic effect w/ AIIA. Faster elimination w/ cholestyramine. Enhanced nephrotoxicity of cyclosporine. Monitor for hypoglycaemia w/ oral antidiabetics eg, sulphonylureas, nateglinide. Not recommended w/ other NSAIDs. Closely monitor patients in concomitant use w/ pemetrexed.
Click to view Mobic detailed prescribing information
Storage
View Mobic storage conditions for details to ensure optimal shelf-life.
Description
View Mobic description for details of the chemical structure and excipients (inactive components).
Action
View Mobic mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AC06 - meloxicam ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.
Presentation/Packing
Form
Mobic tab 7.5 mg
Packing/Price
10 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in